1.1.A Rapid and Sensitive Method for Detection of the T790M Mutation of EGFR in Plasma DNA.
1.1.A Rapid and Sensitive Method for Detection of the T790M Mutation of EGFR in Plasma DNA.
复制标题
1.1.一种快速、灵敏的检测血浆DNA中EGFR T790M突变的方法。
DOI：
10.1007/978-3-319-42044-8_31
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
Kasahara K.
中科院分区：
文献类型：
--
作者：
Kimura H;Nishikawa S;Koba H;Yoneda T;Sone T;Kasahara K.
表皮生长因子受体(EGFR)T790M突变与非小细胞肺癌(NSCLC)对EGFR酪氨酸激酶抑制剂(EGFR-TKIs)耐药有关。本研究的目的是建立一种基于血液的、非侵入性的检测晚期非小细胞肺癌患者EGFRT790M突变的方法，使用一种新的选择性扩增基因特异性序列的方法--Pointman™EGFRDNA富集试剂盒。用Pointman™EGFRDNA富集盒检测血浆中EGFRT790M突变。采用实时定量聚合酶链式反应测定血浆DNA浓度。在52例患者中，41例患者在EGFR-TKIs术后采集了血浆样本。41例患者中有19例(46.3%)在疾病进展为EFGR-TKI后用Pointman™EGFR DNA富集盒检测到其血浆DNA中有EGFRT790M突变。在11例从肿瘤组织中检测到T790M突变的病例中，10例(90.9%)在血浆DNA中也检测到T790M突变。T790M携带者与无T790M携带者的无进展生存期无明显差异。定点™是检测血浆EGFRT790M突变状态的有效方法
Epidermal growth factor receptor (EGFR) T790M mutation is associated with resistance to EGFR tyrosine kinase inhibitors’ (EGFR-TKIs) in non-small cell lung cancer (NSCLC). The aims of this study are to develop a blood-based, non-invasive approach to detecting the EGFR T790M mutation in advanced NSCLC patients, using PointMan™ EGFR DNA Enrichment Kit which is a novel method for selective amplification of genotype specific sequences.Pairs of blood samples and tumor tissues were collected from NSCLC patients with an EGFR activating mutation and who were resistant to EGFR-TKI treatment. EGFR T790M mutation in plasma DNA were detected using the PointMan™ EGFR DNA Enrichment Kit. The concentrations of plasma DNA were determined using quantitative real-time PCR.Of the 52 patients enrolled in this study, 41 of the patients’ plasma samples were collected at post EGFR-TKIs. Nineteen (46.3 %) of the 41 patients had an EGFR T790M mutation in their plasma DNA as detected using the PointMan™ EGFR DNA Enrichment Kit after disease progression to EFGR-TKI. Of 11 cases with a detected T790M mutation from tumor tissues, 10 (90.9 %) also had a detectable T790M mutation in the plasma DNA. There was no difference in the progression-free survival between patients with T790M and those without T790M.The PointMan™ proved to be a useful method for determining plasma EGFR T790M mutation status